Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Restructuring Costs (2024 - 2025)

Tvardi Therapeutics' Restructuring Costs history spans 2 years, with the latest figure at $1.2 million for Q4 2025.

  • On a quarterly basis, Restructuring Costs fell 22.6% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 million, a 0.63% increase, with the full-year FY2025 number at $5.2 million, up 120.57% from a year prior.
  • Restructuring Costs hit $1.2 million in Q4 2025 for Tvardi Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Restructuring Costs for TVRD hit a ceiling of $2.4 million in Q1 2024 and a floor of $164000.0 in Q2 2024.